Imatinib mesylate has been studied as a maintenance therapy in patients with new c-kit-positive AML after induction and post-remission therapy; though the median PFS for younger patients ( < 60 years of age) was 52.1 months, which is longer relative to the historical controls, the study had many limitations, including a small sample size [178]. Here, KIT is linked to acute myeloid leukemia.